Antilipidemic Drugs

Correct Answer

B — Atorvastatin, rosuvastatin, and pitavastatin

Rationale

Atorvastatin, rosuvastatin, and pitavastatin are classified as long half-life statins. This property has practical implications for dosing flexibility: long half-life statins maintain adequate hepatic drug exposure regardless of when during the day they are taken, and rosuvastatin's extended half-life also makes alternate-day dosing feasible for patients who cannot tolerate daily administration. Simvastatin, lovastatin, pravastatin, and fluvastatin are all classified as short half-life statins, for which evening dosing is generally preferred to align peak drug concentration with the nocturnal peak in hepatic cholesterol synthesis.

Correct Answer

D — Cyclosporine

Rationale

Cyclosporine is classified as an inhibitor of both cytochrome P450 3A4 and hepatic organic anion-transporting polypeptide 1B1 uptake transporters. This dual inhibitory profile makes cyclosporine one of the most pharmacokinetically challenging co-medications in statin therapy: it blocks both the hepatic entry of statins via uptake transporters and their cytochrome P450 3A4-mediated metabolism, raising statin plasma concentrations substantially and creating a clinically important risk of myopathy. Fenofibrate is classified as a fibrate and does not inhibit these pathways. Clarithromycin is classified as a macrolide antibiotic and inhibits cytochrome P450 3A4 but not hepatic organic anion-transporting polypeptide 1B1 transporters as a primary mechanism. Itraconazole is classified as an azole antifungal cytochrome P450 3A4 inhibitor, not a dual-pathway inhibitor in the same sense as cyclosporine.

Correct Answer

A — Rosuvastatin

Rationale

Rosuvastatin is classified as the statin most appropriate for alternate-day dosing in statin-intolerant patients. Among the available statins, rosuvastatin has one of the longest half-lives, which allows it to maintain meaningful low-density lipoprotein receptor upregulation even when administered every other day or two to three times per week rather than daily. Simvastatin, pravastatin, and lovastatin are all short half-life statins; their plasma concentrations fall too rapidly between doses to sustain adequate hepatic drug exposure with less than daily administration, making alternate-day dosing impractical for those agents.

Correct Answer

C — Simvastatin, lovastatin, pravastatin, and fluvastatin

Rationale

The short half-life statin group consists of exactly four members: simvastatin, lovastatin, pravastatin, and fluvastatin. These four agents reach peak plasma concentrations relatively quickly after each dose and clear rapidly, making evening dosing preferable to align peak drug exposure with the nocturnal peak in hepatic cholesterol synthesis. The long half-life group consists of atorvastatin, rosuvastatin, and pitavastatin — three agents for which dosing time is less critical because they maintain sustained hepatic drug concentrations throughout the 24-hour period. The distractors each mix at least one long half-life agent into the short half-life group, or substitute pitavastatin for fluvastatin — pitavastatin is a long half-life statin and does not belong in the short half-life group.

Correct Answer

B — Itraconazole

Rationale

Itraconazole is classified as a strong cytochrome P450 3A4 inhibitor belonging to the azole antifungal class. Azole antifungals as a group — including itraconazole and ketoconazole — are among the most potent cytochrome P450 3A4 inhibitors encountered in clinical practice and create a high risk of muscle toxicity when combined with cytochrome P450 3A4-metabolized statins such as atorvastatin, simvastatin, and lovastatin. Clarithromycin is a macrolide antibiotic and a strong cytochrome P450 3A4 inhibitor, but it belongs to the macrolide antibiotic class, not the azole antifungal class. Gemfibrozil is classified as a fibrate and inhibits hepatic organic anion-transporting polypeptide 1B1 transporters and statin glucuronidation pathways rather than cytochrome P450 3A4. Amiodarone is classified as a Vaughan Williams Class III antiarrhythmic agent and is a moderate cytochrome P450 3A4 inhibitor, not a strong one.

Correct Answer

D — Fluconazole

Rationale

Fluconazole is classified as a cytochrome P450 2C9 inhibitor. This classification is relevant to statin therapy because fluvastatin is the one statin metabolized primarily by cytochrome P450 2C9 rather than cytochrome P450 3A4; co-administration of fluconazole with fluvastatin raises fluvastatin plasma concentrations and increases muscle toxicity risk. Itraconazole is an azole antifungal classified as a cytochrome P450 3A4 inhibitor, not a cytochrome P450 2C9 inhibitor. Amiodarone is classified as a Vaughan Williams Class III antiarrhythmic agent and is a moderate cytochrome P450 3A4 inhibitor, not a cytochrome P450 2C9 inhibitor. Cyclosporine is classified as an inhibitor of both cytochrome P450 3A4 and hepatic organic anion-transporting polypeptide 1B1 uptake transporters.

Correct Answer

A — Myopathy: creatine kinase greater than 10 times the upper limit of normal; rhabdomyolysis: creatine kinase greater than 40 times the upper limit of normal with myoglobinuria

Rationale

Statin-associated muscle toxicity is classified by defined creatine kinase thresholds. Myalgia is muscle pain or weakness without creatine kinase elevation. Myopathy is defined as muscle symptoms accompanied by creatine kinase elevation greater than 10 times the upper limit of normal — this is uncommon at approximately one per ten thousand patient-years. Rhabdomyolysis is the most severe form, defined by creatine kinase elevation greater than 40 times the upper limit of normal together with myoglobinuria and risk of acute kidney injury — this occurs in roughly one to three per hundred thousand patient-years. Myoglobinuria is part of the defining constellation for rhabdomyolysis; the 3-times threshold applies to when routine creatine kinase monitoring might prompt clinical concern, not to the definition of myopathy itself.

Correct Answer

C — A substantial proportion of reported statin muscle symptoms reflects the nocebo effect — symptoms driven by negative expectations rather than direct pharmacological toxicity — meaning most patients can be successfully rechallenged

Rationale

When muscle symptoms during statin therapy can be replicated during blinded placebo periods at similar rates, this quantifies a nocebo component: symptoms arising from negative expectations, media-amplified beliefs about statin harm, or non-pharmacological factors rather than from direct drug toxicity. This finding has an important clinical implication — most patients who have discontinued statins due to perceived muscle intolerance can successfully restart if the nocebo component is addressed through patient education and systematic rechallenge. True statin-attributable myopathy (creatine kinase greater than 10 times upper limit of normal) and rhabdomyolysis are genuine pharmacological events that are substantially less common than patient-reported symptom rates suggest. Statins do not have prolonged tissue accumulation that would explain crossover symptom persistence, and placebo excipients do not independently cause muscle toxicity.

Correct Answer

B — Rosuvastatin's long half-life maintains hepatic drug concentrations sufficient to sustain low-density lipoprotein receptor upregulation between every-other-day doses; simvastatin's short half-life causes concentrations to fall below effective levels between doses

Rationale

The viability of alternate-day dosing depends on pharmacokinetics. Rosuvastatin has a long half-life — among the longest of any statin — which allows it to maintain hepatic drug concentrations that continue to drive low-density lipoprotein receptor upregulation even on drug-free days. Simvastatin, by contrast, has a short half-life with rapid hepatic clearance; its active drug exposure falls substantially within hours of each dose, making alternate-day administration insufficient to maintain meaningful receptor upregulation between doses. Rosuvastatin's alternate-day strategy therefore exploits a real pharmacokinetic advantage, not superior potency per dose or tissue accumulation. The hydrophilic nature of rosuvastatin contributes to its liver selectivity but is not the direct reason alternate-day dosing is viable — that distinction rests on half-life.

Correct Answer

D — Statins impair glucose transporter expression in skeletal muscle and adipose tissue, reduce insulin secretion from pancreatic beta cells, and increase hepatic glucose production — all through inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase

Rationale

Statin-associated new-onset diabetes results from multiple interconnected effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition: impaired expression of glucose transporter proteins in skeletal muscle and adipose tissue reduces peripheral glucose uptake; reduced insulin secretion from pancreatic beta cells diminishes the glucose-lowering response to meals; and increased hepatic glucose production adds to fasting hyperglycemia. The fact that naturally occurring genetic variants that reduce 3-hydroxy-3-methylglutaryl coenzyme A reductase activity produce the same pattern — established by Mendelian randomization — confirms this is an on-target pharmacological effect intrinsic to the mechanism of enzyme inhibition, not a drug-specific artifact. Statins do not impair renal glucose excretion, do not increase hepatic insulin clearance through cytochrome P450 induction, and do not cause diabetes through non-alcoholic fatty liver disease promotion.

Correct Answer

A — The risk is concentrated in patients who already carry conventional diabetes risk factors — impaired fasting glucose, metabolic syndrome, obesity, or older age; patients without any of these risk factors have negligible absolute risk

Rationale

Statin-associated new-onset diabetes occurs almost exclusively in patients who already have pre-diabetes risk factors. A patient with impaired fasting glucose, metabolic syndrome, obesity, or older age is on a trajectory toward type 2 diabetes independent of statin therapy; statins modestly accelerate the crossing of the diagnostic threshold. In patients without any conventional diabetes risk factors, the absolute risk increase from statin therapy is negligible. This means the new-onset diabetes risk is concentrated in precisely the population that already warrants glucose monitoring and lifestyle counseling regardless of statin use. The risk is dose-dependent — higher-intensity regimens carry greater diabetogenic risk than moderate-intensity regimens — so the statement that moderate-intensity statins carry no risk is inaccurate.

Correct Answer

C — Cholesterol and isoprenoid intermediates produced by the mevalonate pathway are essential for fetal organogenesis, neural myelination, and steroid hormone synthesis; statin inhibition of this pathway during pregnancy carries teratogenic risk

Rationale

The mevalonate pathway produces not only cholesterol but also non-sterol isoprenoid intermediates that are indispensable for normal fetal development: cholesterol is required for cell membrane synthesis, myelination of developing neural tissue, and the production of steroid hormones including glucocorticoids, mineralocorticoids, and sex steroids. Statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase blocks the entire mevalonate pathway, depriving the developing fetus of substrates it cannot synthesize adequately from other sources during critical developmental windows. The contraindication is categorical — statins should be discontinued promptly upon confirmed pregnancy, and women of childbearing potential on statin therapy should use reliable contraception. The contraindication is not based on placental low-density lipoprotein receptor inhibition, on maternal cholesterol depletion below fetal needs, or on placental cytochrome P450 bioactivation to toxic metabolites.

Correct Answer

B — In dialysis patients, the dominant cause of cardiovascular death shifts to uremic cardiomyopathy and arrhythmia rather than atherothrombotic plaque rupture, so reducing low-density lipoprotein cholesterol does not address the primary cause of mortality

Rationale

In patients not yet on dialysis, cardiovascular deaths are predominantly atherothrombotic — driven by plaque formation and rupture in which low-density lipoprotein cholesterol is a central pathogenic factor. Statin-mediated low-density lipoprotein cholesterol reduction therefore translates into meaningful reductions in cardiovascular events in this population, as demonstrated by large randomized trials including the Study of Heart and Renal Protection. In patients receiving hemodialysis, the pathophysiology of cardiovascular death changes substantially: uremic cardiomyopathy, left ventricular hypertrophy, myocardial fibrosis, and arrhythmia driven by the uremic milieu become the dominant causes of mortality. These mechanisms are not addressed by low-density lipoprotein cholesterol reduction, explaining the neutral results of dedicated dialysis trials. Hemodialysis does not remove statins to a clinically relevant degree, and uremia does not prevent statin-mediated low-density lipoprotein receptor upregulation.

Correct Answer

D — Hepatic cholesterol synthesis peaks between midnight and 2 a.m.; evening dosing of a short-half-life statin times peak plasma drug concentration to coincide with this period of maximal synthetic activity, maximizing enzyme inhibition and low-density lipoprotein receptor upregulation

Rationale

Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity follows a circadian pattern, with cholesterol synthesis peaking between midnight and 2 a.m. Simvastatin has a short half-life, so its plasma concentration rises and falls relatively quickly after each dose. Taking it in the evening aligns the peak drug concentration with the nocturnal peak in reductase activity, producing more complete inhibition of cholesterol synthesis and therefore greater compensatory low-density lipoprotein receptor upregulation. This dosing strategy does not apply to long-half-life statins — atorvastatin, rosuvastatin, and pitavastatin — because their sustained plasma concentrations provide continuous reductase inhibition throughout the 24-hour period regardless of when the dose is taken. The timing recommendation is not based on gastrointestinal absorption enhancement, muscle toxicity risk, or receptor expression patterns.

Correct Answer

C — Hold atorvastatin temporarily for four to six weeks to assess whether symptoms resolve, then rechallenge with the same or a different statin at a lower dose

Rationale

This patient has statin-associated myalgia with mild creatine kinase elevation — 2.5 times the upper limit of normal is well below the 10-times threshold that defines myopathy, and the absence of myoglobinuria excludes rhabdomyolysis. The stepwise management protocol for this scenario calls for a temporary hold of four to six weeks: if symptoms resolve during this period, statin causality is supported, and rechallenge with the same agent at a lower dose or a switch to a different statin (rosuvastatin, pravastatin, or fluvastatin are often preferred for rechallenge) is appropriate. Permanent discontinuation is not warranted — outright avoidance of all statins is rarely necessary. A large proportion of patients with self-reported statin muscle symptoms can tolerate rechallenge, particularly given the documented contribution of the nocebo effect. Hospitalization for intravenous fluids is reserved for confirmed rhabdomyolysis with myoglobinuria and acute kidney injury risk.

Correct Answer

A — Bile acid sequestrants, because they are not systemically absorbed and therefore do not reach the fetal circulation

Rationale

Bile acid sequestrants — cholestyramine, colestipol, and colesevelam — act entirely within the intestinal lumen by binding bile acids and preventing their reabsorption. Because they are not absorbed into the systemic circulation, they cannot reach the placenta or the fetal circulation and are considered safe for use during pregnancy. They are the only lipid-lowering drug class with an established safety record in pregnancy, though their low-density lipoprotein cholesterol reduction of 15 to 25 percent is modest compared with statins. Ezetimibe is absorbed systemically and reaches the fetal circulation; its safety in pregnancy has not been established. Fibrates are absorbed systemically and carry potential teratogenic risk. Proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibodies are large molecules but do cross the placenta via neonatal Fc receptor-mediated transport, particularly in the second and third trimesters, and their safety in pregnancy is not established.

Correct Answer

B — Continue the statin and manage the new diabetes with standard care, because the cardiovascular benefit of statin therapy substantially exceeds the modest incremental diabetes risk — approximately five cardiovascular events prevented for every one additional diabetes case

Rationale

Statin therapy does modestly increase the risk of new-onset type 2 diabetes, and this patient's diabetes may have been accelerated by his statin. However, the cardiovascular benefit of statin therapy in patients with established atherosclerotic cardiovascular disease is large: across statin trials in high-risk populations, approximately five major cardiovascular events are prevented for every one additional case of diabetes attributable to the drug. A patient who develops diabetes on statin therapy has not experienced net harm — the cardiovascular protection gained exceeds the diabetes risk incurred. Current guidelines explicitly state that new-onset diabetes on statin therapy is not a reason to discontinue the drug; the diabetes should be managed with standard lifestyle and pharmacological measures while the statin is continued. Switching to moderate-intensity therapy is not appropriate in an established secondary prevention patient. Statin discontinuation while awaiting glucose control would expose this high-risk patient to avoidable cardiovascular events.

Correct Answer

D — In Patient A, atherothrombosis remains the dominant mechanism of cardiovascular death, so reducing low-density lipoprotein cholesterol provides meaningful event reduction; in Patient B, the dominant cardiovascular cause of death has shifted to uremic cardiomyopathy and arrhythmia — mechanisms that are not addressed by low-density lipoprotein cholesterol lowering

Rationale

The divergence in statin recommendations between pre-dialysis and dialysis chronic kidney disease patients reflects a shift in the underlying pathophysiology of cardiovascular mortality. In Patient A, with stage 4 chronic kidney disease but no yet on dialysis, atherothrombotic disease driven by low-density lipoprotein cholesterol accumulation and plaque formation remains the dominant mechanism of cardiovascular death — the same mechanism that statins address. Large randomized trials, including the Study of Heart and Renal Protection, have demonstrated meaningful cardiovascular event reduction with statin therapy in this population. In Patient B, after years of dialysis, the uremic milieu produces structural cardiac changes — left ventricular hypertrophy, myocardial fibrosis, and electrophysiological instability — that cause death from pump failure and arrhythmia rather than atherothrombosis. Dedicated dialysis trials have found no cardiovascular mortality benefit from statin initiation in this setting, despite meaningful low-density lipoprotein cholesterol reduction. Hemodialysis does not remove statins to clinically relevant levels, uremia does not prevent statin-mediated low-density lipoprotein receptor upregulation, and statin accumulation causing rhabdomyolysis is not the reason for the neutral trial results in dialysis patients.